Literature DB >> 10146978

Quality-of-life assessment in respiratory disease: an examination of the content and validity of four questionnaires.

M E Hyland1.   

Abstract

Four recent questionnaires for measuring the quality of life of patients with respiratory disease (Chronic Respiratory Disease Questionnaire, St George's Respiratory Questionnaire, Living with Asthma Questionnaire, and Asthma Quality of Life Questionnaire) differ in the content and style of the items used. Differences in content arise over the use or emphasis on symptom items, functional limitation (activity) items, and emotion items. These differences stem in part from the different methods used for item selection and refinement, which include selecting the most 'important' items, qualitative analysis for clarity, ratings of distress, and psychometric analysis. Despite these differences, there is considerable evidence for content validity of all four questionnaires. Because quality of life is so poorly developed as a theoretical construct, the demonstrable statement that all 4 questionnaires have construct validity provides little information about the questionnaires.

Entities:  

Mesh:

Year:  1992        PMID: 10146978     DOI: 10.2165/00019053-199202010-00006

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  18 in total

1.  Measuring health status: what are the necessary measurement properties?

Authors:  G H Guyatt; B Kirshner; R Jaeschke
Journal:  J Clin Epidemiol       Date:  1992-12       Impact factor: 6.437

2.  How should health status measures be assessed? Cautionary notes on procrustean frameworks.

Authors:  J I Williams; C D Naylor
Journal:  J Clin Epidemiol       Date:  1992-12       Impact factor: 6.437

3.  Selection of items and avoidance of bias in quality of life scales.

Authors:  M E Hyland
Journal:  Pharmacoeconomics       Date:  1992-03       Impact factor: 4.981

4.  Standardisation of quality of life trials: an industry perspective.

Authors:  B Spilker
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

5.  Influence of demographic and disease related factors on the degree of distress associated with symptoms and restrictions on daily living due to asthma in six countries.

Authors:  F H Quirk; C M Baveystock; R Wilson; P W Jones
Journal:  Eur Respir J       Date:  1991-02       Impact factor: 16.671

6.  A scale for assessing quality of life in adult asthma sufferers.

Authors:  M E Hyland; S Finnis; S H Irvine
Journal:  J Psychosom Res       Date:  1991       Impact factor: 3.006

7.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire.

Authors:  P W Jones; F H Quirk; C M Baveystock; P Littlejohns
Journal:  Am Rev Respir Dis       Date:  1992-06

Review 8.  Quality of life instruments in the evaluation of new drugs.

Authors:  R Jaeschke; G H Guyatt; D Cook
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

9.  A measure of quality of life for clinical trials in chronic lung disease.

Authors:  G H Guyatt; L B Berman; M Townsend; S O Pugsley; L W Chambers
Journal:  Thorax       Date:  1987-10       Impact factor: 9.139

10.  Patients' perception of distress due to symptoms and effects of asthma on daily living and an investigation of possible influential factors.

Authors:  F H Quirk; P W Jones
Journal:  Clin Sci (Lond)       Date:  1990-07       Impact factor: 6.124

View more
  5 in total

1.  Defining quality of life.

Authors:  F Quirk; P W Jones
Journal:  Pharmacoeconomics       Date:  1992-09       Impact factor: 4.981

2.  A reformulation of quality of life for medical science.

Authors:  M E Hyland
Journal:  Qual Life Res       Date:  1992-08       Impact factor: 4.147

Review 3.  Salmeterol. An appraisal of its quality-of-life benefits and potential pharmacoeconomic positioning in asthma.

Authors:  D H Peters; D Faulds
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

Review 4.  Budesonide. An appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in asthma.

Authors:  R Davis; D McTavish
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

Review 5.  Assessing quality of life in chronic non-specific lung disease--a review of empirical studies published between 1980 and 1994.

Authors:  A R Maillé; A A Kaptein; J C de Haes; W T Everaerd
Journal:  Qual Life Res       Date:  1996-04       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.